BioSpace News Archive

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced leadership promotions and a new medical director.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro’s “LD 500" Virtual Investor Conference, on Wednesday, September 02, 2020 3:40 PM Eastern Time.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.

Pharmaceutical Associates, Inc. announced that the company has been awarded a three-year contract from HealthTrust Purchasing Group as a supplier of pharmaceutical products to its Membership nationwide.

Centene Corporation (NYSE: CNC) today announced three executive leadership appointments to support the company’s continued growth

RLS (USA) Inc., (Radioisotope Life Sciences) has purchased General Electric’s (GE) U.S. radiopharmacy network, making it the largest pure molecular imaging focused firm in the United States.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be presenting at the LD Micro 500 Virtual Investor conference being held virtually on September 1-4, 2020.

HDT Bio Corp. is bringing immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications.

CM Life Sciences, Inc. (the “Company”) announced today that it priced its initial public offering of 38,500,000 units at $10.00 per unit.

Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered novel anti-human CCR8 mAbs at the 16th PEGS Boston Summit.